Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Eugenio Fardella, Giada Zanirato, Martina Magni, Nicole Caldarelli, Annalisa Chiappella, Anna Dodero, Silva Ljevar, Lorella Orsucci, Alessandro Re, Sara Usai, Vittorio Stefoni, Claudia Castellino, Francesca Gaia Rossi, Antonio Pinto, Cristiana Carniti, Paolo Corradini

Blood (2023) 142 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2023-189215

Published: 2023

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2023-180036

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Blood (2023) 142 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2023-184455

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Antonella Anastasia, Chiara Pagani, Alessandro Re, Marina Motta, Giacomo Pata, Enrico Damiani, Lisa Gandolfi, Rosa Daffini, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 11951–11953.

https://doi.org/10.1182/blood-2022-164792

Published: 2022

Journal Articles

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Blood (2022) 140 (Supplement 1): 9375–9377.

https://doi.org/10.1182/blood-2022-159949

Published: 2022

Journal Articles

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Blood (2021) 138 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2021-148431

Published: 2021

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Journal Articles

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

Chiara Pagani, Chiara Rusconi, Alessia Dalla Pria, Emanuele Ravano, Philipp Schommers, Mariana Bastos-Oreiro, Luisa Verga, Guido Gini, Michele Spina, Luca Arcaini, Sara Steffanoni, Davide Dalu, Chiara Cattaneo, Fabio Facchetti, Giuseppe Rossi, Alessandra Tucci, Alessandro Re

Blood (2021) 138 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2021-151149

Published: 2021

Journal Articles

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2021-149649

Published: 2021

Journal Articles

Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases

Blood (2021) 138 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2021-151174

Published: 2021

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Alessandra Tucci, MD, Alessandro Re, MD, Chiara Pagani, MD, Anna Guidetti, Anna Dodero, Fabrizio Marino, MD, Ivana Casaroli, MD, Giulia Soverini, MD, Rosa Daffini, MD, Monica Balzarotti, Giulia Campostrini, Luisa Lorenzi, MD, Piera Balzarini, Fabio Facchetti, Carmelo Carlo-Stella, MD, Paolo Corradini, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139977

Published: 2020

Journal Articles

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134875

Published: 2020

NARROW

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only